Explore the words cloud of the proLungPlasma project. It provides you a very rough idea of what is the project "proLungPlasma" about.
The following table provides information about the project.
|Coordinator Country||Germany [DE]|
|Total cost||2˙772˙527 €|
|EC max contribution||2˙772˙527 € (100%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2015-07-01 to 2017-12-31|
Take a look of project's partnership.
The objective of “proLungPlasma” is the clinical validation of a lung cancer test, which detects DNA methylation of the specific biomarker mSHOX2. Methylation of DNA is an important epigenetic process involved in fundamental biological processes as development and cell differentiation. Aberrant DNA methylation plays a major role in cancer development. Epigenomics is very successfully engaged in epigenetic research since 1998 resulting in an outstanding proprietary platform for epigenetic biomarker discovery for cancer. Epigenomics is now market leader in epigenetic biomarker test kits detecting most frequently occurring forms of cancer as colorectal and lung cancer from different sample materials. Lung Cancer is the most deadly of all cancer diseases. Unfortunately, lung cancer screening by Low Dose Computer Tomography (LDCT) is burdened by unacceptably high false positive rates. The newly developed Epi proLung Plasma Reflex Assay is urgently required as a tool for reducing false positive rates. Therefore, the Epi proLung Plasma Reflex Assay is a highly anticipated pre-requisite for successful implementation of lung cancer screening in Europe. This business innovation project will validate the Epi proLung Plasma Reflex Assay for the diagnosis of lung cancer in plasma under the upcoming new IVD regulation. The validation process to be performed in this business innovation project will be used as a blueprint for the standardized validation of all further epigenetic biomarker blood tests. Epigenomics’ established test platform, its product development and regulatory expertise, and the standardized validation process are expected to kick-off further strong growth on major global MDx markets.
|Registration Documents||Documents, reports||2019-05-30 12:55:42|
Take a look to the deliverables list in detail: detailed list of proLungPlasma deliverables.
|year||authors and title||journal||last update|
Gunter Weiss, Anne Schlegel, Denise Kottwitz, Thomas KÃ¶nig, Reimo Tetzner
Validation of the SHOX2 / PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease
published pages: 77-84, ISSN: 1556-0864, DOI: 10.1016/j.jtho.2016.08.123
|Journal of Thoracic Oncology 12/1||2019-07-08|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROLUNGPLASMA" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "PROLUNGPLASMA" are provided by the European Opendata Portal: CORDIS opendata.
Collaboration for innovation: Establishment of a pan-nematode drug development platformRead More
Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients with Bone MetastasisRead More
Global Alliance for Chronic Diseases SecretariatRead More